Evidence map›Paper›PMID 32556207›Full record

ArticleInternational health2021

Leveraging routine viral load testing to integrate diabetes screening among patients on antiretroviral therapy in Malawi.

Victor Singano, Joep J van Oosterhout, Austrida Gondwe, Pearson Nkhoma, Fabian Cataldo, Emmanuel Singogo, Joe Theu, Wilson Ching'ani, Mina C Hosseinpour, Alemayehu Amberbir

Open access · goldAbstract read
In one paragraph

Article in International health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 6 citations in OpenAlex.

  1. Dried Blood Spots to Assess Cardiovascular-Kidney-Metabolic Health.Journal of the American Heart Association · 2025
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Victor SinganoDignitas International, Zomba, Malawi.
Joep J van OosterhoutDignitas International, Zomba, Malawi.
Austrida GondweDignitas International, Zomba, Malawi.
Pearson NkhomaDignitas International, Zomba, Malawi.
Fabian CataldoDignitas International, Zomba, Malawi.
Emmanuel SingogoDignitas International, Zomba, Malawi.
Joe TheuDignitas International, Zomba, Malawi.
Wilson Ching'aniMinistry of Health, District Health Office, Zomba, Malawi.
Mina C HosseinpourUniversity of North Carolina-Malawi Project, Lilongwe, Malawi.
Alemayehu AmberbirDignitas International, Zomba, Malawi.
Dignitas International · MWMinistry of Health · MWUniversity of Malawi · MW

Funding

Malawi HIV Implementation Research Scientist Training Program (MHIRST)D43TW010060 · FIC · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MINA CHRISTINE HOSSEINIPOUR, Victor Mwapasa · 2015 to 2026
$3.8M
FIC NIH HHS D43 TW010060
6 · The paper itself

Abstract

backgroundPeople living with HIV are at an increased risk of diabetes mellitus due to HIV infection and exposure to antiretroviral therapy (ART). Despite this, integrated diabetes screening has not been implemented commonly in African HIV clinics. Our objective was to explore the feasibility of integrating diabetes screening into existing routine HIV viral load (VL) monitoring and to determine a group of HIV patients that benefit from a targeted screening for diabetes.

methodsA mixed methods study was conducted from January to July 2018 among patients on ART aged≥18 y and healthcare workers at an urban HIV clinic in Zomba Central Hospital, Malawi. Patients who were due for routine VL monitoring underwent a finger-prick for simultaneous point-of-care glucose measurement and dried blood spot sampling for a VL test. Diabetes was diagnosed according to WHO criteria. We collected demographic and medical history information using an interviewer-administered questionnaire and electronic medical records. We conducted focus group discussions among healthcare workers about their experience and perceptions regarding the integrated diabetes screening program.

resultsOf patients undergoing routine VL monitoring, 1316 of 1385 (95%) had simultaneous screening for diabetes during the study period. The median age was 44 y (IQR: 38-53); 61% were female; 28% overweight or obese; and median ART duration was 83 mo (IQR: 48-115). At baseline, median CD4 count was 199 cells/mm3 (IQR: 102-277) and 50% were in WHO clinical stages I or II; 45% were previously exposed to stavudine and 88% were virologically suppressed (<1000 copies/mL).  Diabetes prevalence was 31/1316 (2.4%). Diabetes diagnosis was associated with age ≥40 y (adjusted OR [aOR] 7.44; 95% CI: 1.74 to 31.80), being overweight and/or obese (aOR 2.46; 95% CI: 1.13 to 5.38) and being on a protease inhibitor-based ART regimen (aOR 5.78; 95% CI: 2.30 to 14.50). Healthcare workers appreciated integrated diabetes screening but also reported challenges including increased waiting time, additional workload and inadequate communication of results to patients.

conclusionsIntegrating diabetes screening with routine VL monitoring (every 2 y) seems feasible and was valued by healthcare workers. The additional cost of adding diabetes screening into VL clinics requires further study and could benefit from a targeted approach prioritizing patients aged ≥40 y, being overweight/obese and on protease inhibitor-based regimens.

Indexed as

Anti-HIV AgentsDiabetes MellitusHIV InfectionsAdultAnti-Retroviral AgentsCD4 Lymphocyte CountFemaleHumansMalawiMaleViral LoadAnti-HIV AgentsAnti-Retroviral AgentsdiabetesHIVintegrationscreeningviral load

Identifiers

PMID32556207
PMCPMC7902676
OpenAlexW3036109938

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.